Effect of olanzapine on functional responses from sensitized D1-dopamine receptors in rats with neonatal dopamine loss

Neuropsychopharmacology

Volumn 25, Issue 2, 2001, Pages 224-233

  Moy, Sheryl S ^a   Knapp, Darin J ^a   Breese, George R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic drugs; D1 dopamine receptor; Fos; Olanzapine; Self injurious behavior; Sensitization

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; DESIPRAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; OLANZAPINE; OXIDOPAMINE; PARGYLINE; PROTEIN FOS; QUINPIROLE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOMUTILATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; LOCOMOTION; MALE; NERVE CELL LESION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; RECEPTOR SENSITIVITY; SENSITIZATION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ADRENERGIC AGENTS; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BENZODIAZEPINES; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; FEMALE; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1;

EID: 0034989476     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00224-X     Document Type: Article

References (38)

1. Interaction between dopaminergic and serotonergic systems after neonatal 6-OHDA lesions
2. Evaluation of risperidone in the neonatal 6-hydroxydopamine model of Lesch-Nyhan syndrome
3. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
4. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double blind olanzapine trial
5. Behavioral differences between neonatal and young adult 6-hydroxydopamine-treated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine
6. Neonatal-6-hydroxydopamine treatment: Model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome
7. Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine
8. Neurobiology of D1 dopamine receptors after neonatal-6-OHDA treatment: Relevance to Lesch-Nyhan disease
9. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: Functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats
10. Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: Effects of 6-hydroxydopamine
11. Rats given dopamine-depleting brain lesions as neonates are subsensitive to dopaminergic antagonists as adults
12. Radioreceptor binding profile of the atypical antipsychotic olanzapine
13. Olanzapine: A basic science update
14. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-Methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats
15. Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors
16. 1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats
17. 1-dopamine receptor sensitization in neonatal 6-OHDA-lesioned rats is blocked by an NMDA antagonist
18. Pharmacological evaluation of atypical neuroleptics in the 6-OHDA model of Lesch-Nyhan syndrome
19. 2-like" agonist RU 24213
20. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine
21. Neuranatomical characterization of Fos induction in rat behavioral models of anxiety
22. Effects of acute and chronic 1,3-butanediol treatment on central nervous system function: A comparison with ethanol
23. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: Behavioral effects and induction of c-fos-like immunoreactivity
24. Behavioral effects of clozapine and dopamine receptor subtypes
25. 2C receptors after chronic treatment with clozapine, chlorpromazine, and three putative atypical antipsychotic drugs
26. A familial disorder of uric acid metabolism and central nervous system function
27. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome
28. Olanzapine: A new atypical antipsychotic drug
29. Dopamine D-1 and D-2 receptors in relation to reward and performance: A case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs
30. Behavioral pharmacology of olanzapine: A novel antipsychotic drug
31. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent
32. Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine
33. 2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients
34. Effects of olanzapine on regional C-Fos expression in rat forebrain
35. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
36. Olanzapine-induced Fos expression in the rat forebrain; cross-tolerance with haloperidol and clozapine
37. Clinical, post-mortem, biochemical, and therapeutic observations on the Lesch-Nyhan syndrome with particular reference to the neurological manifestations
38. 2A, and muscarinic receptors